Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers.
CEO: Charlene Liao, Ph.D.
Company Headquarters: Palo Alto, CA